Real-world Experience with Tafamidis in Patients with Cardiac Amyloidosis

European Cardiology Review · Published 2026-04-15 · DOI 10.15420/ecr.2026.21.s1.po6

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.15420/ecr.2026.21.s1.po6

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• The Biological Mechanisms of Frailty: Focusing on Cellular Senescence · European Cardiology Review · 2026 · Same journal
• Beyond Weight Reduction: Obesity as a Therapeutic Pivot in Cardio–Renal–Metabolic Disease and Drug Management · European Cardiology Review · 2026 · Same journal
• Calcium Channel Blockers: The Only Pharmacological Choice · European Cardiology Review · 2026 · Same journal
• Preterm Birth and Maternal Cardiovascular Risk · European Cardiology Review · 2026 · Same journal
• Experience with the Use of Quinidine in Patients with Brugada Syndrome · European Cardiology Review · 2026 · Same journal
• Cardiac Pharmacological Challenges in a Patient with Panhypopituitarism and Chronic Pericardial Effusion · European Cardiology Review · 2026 · Same journal
• Aspirin Hypersensitivity in Acute Coronary Syndrome: Literature Review and Case Report · European Cardiology Review · 2026 · Same journal
• Are the Patients We Refer for Mitraclip Receiving Optimal Medical Therapy? Experience in a Tertiary Care Hospital · European Cardiology Review · 2026 · Same journal
• Short- and Medium-term Results of Surgical versus Transcatheter Repair in Severe Tricuspid Regurgitation · European Cardiology Review · 2026 · Same journal
• Effectiveness of Lipid-lowering Therapy in Secondary Prevention Across Spanish Regions: A National Registry Analysis · European Cardiology Review · 2026 · Same journal